BioWorld - Monday, February 9, 2026

BARDA
BARDA RSS Feed RSS

Infection

BARDA offers $100M in prize money for antiviral development

Feb. 4, 2026
No Comments
Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families.
Read More

BARDA offers $100M in prize money for antiviral development

Feb. 4, 2026
No Comments
Looking to fill a treatment gap, the U.S. Biomedical Advanced Research and Development Authority (BARDA) is launching the first stage of a $100 million prize competition to support development of broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families.
Read More
Nonprofit stamp
Biopharma nonprofit deals and grants 2025

Biopharma nonprofit dealmaking and grants stabilize in a new normal

Nov. 4, 2025
By Amanda Lanier
No Comments
Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.
Read More
Nonprofit stamp
Biopharma nonprofit deals and grants 2025

Biopharma nonprofit dealmaking and grants stabilize in a new normal

Nov. 3, 2025
By Amanda Lanier
No Comments
Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.
Read More
Gloved hands holding mRNA vaccine vial

US HHS cancels 22 BARDA mRNA vaccine contracts

Aug. 6, 2025
By Mari Serebrov
No Comments
Cancel culture continues at the U.S. Department of Health and Human Services (HHS) as it observes National Immunization Awareness Month with another strike against vaccines. This time, a $500 million strike specifically targets 22 mRNA vaccine R&D programs at the Biomedical Advanced Research and Development Authority (BARDA), marking the beginning of the end of BARDA’s funding for mRNA vaccines.
Read More

US HHS awards Shionogi $375M to develop COVID-19 PrEP therapy

Jan. 21, 2025
By Marian (YoonJee) Chu
Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 pre-exposure prophylaxis. The project was awarded to New Jersey-based Shionogi Inc., a subsidiary of the Osaka, Japan-based pharmaceutical company. S-892216 is an investigational second-generation 3CL protease inhibitor in development as a long-acting injectable for prophylaxis treatment of SARS-CoV-2.
Read More